Related Experiment Video
Updated: Apr 15, 2026
Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
Risk of avoidant/restrictive food intake disorders in patients with inflammatory bowel disease: a matched
Olga Maria Nardone1, Ferdinando D'Amico2, Giulio Calabrese3
1Gastroenterology, Department of Public Health, University of Naples Federico II, Naples, Italy.
Background:
Individuals with inflammatory bowel disease (IBD) often modify their diet to manage symptoms; however, these behaviors may evolve into eating disorders, including avoidant/restrictive food intake disorder (ARFID). We assessed the risk of eating disorders and ARFID in patients with IBD compared with healthy controls (HC), explored differences by age at diagnosis, and examined associations with malnutrition and disability.
Methods:
In this cross-sectional study, adult patients with confirmed IBD, stratified by pediatric- vs adult-onset, were matched with HC. ARFID risk was assessed using the Nine-Item ARFID Screen (NIAS-9) and eating disorders risk with the Eating Attitudes Test-26 (EAT-26). Nutritional status was evaluated with the Patient-Generated Subjective Global Assessment (PG-SGA) and disability with the IBD-Disk and modified IBD-Disk.
Results:
A total of 706 participants completed questionnaires (355 IBD, 351 HC). Eating disorder risk did not differ between groups (11.3% vs 10.8%, P = .91). ARFID risk was higher in IBD (13.5% vs 5.7%, P < .001), with more fear-driven eating (P < .001) and lower picky eating (P < .001) and appetite scores (P = .033). ARFID risk did not differ by age at onset (P = .39). Independent associated factors included active disease (odds ratio [OR] 2.34, 95% confidence interval [CI] 1.10-5.01), malnutrition (OR 2.31, 95% CI 1.04-5.13), dietary changes (OR 4.32, 95% CI 1.92-9.74), and eating disorder risk (OR 7.47, 95% CI 2.95-18.90). Even in remission, ARFID risk remained elevated compared to HC (10.1% vs 5.7%, P = .03).
Conclusions:
ARFID risk in IBD is nearly twice that of HC and strongly associated with disease activity, malnutrition, and disability, supporting the importance of ARFID screening in routine IBD care.
More Related Videos
Related Concept Videos
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
01:17Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:21Inflammatory Bowel Disease V: Surgical Management
Here are some common surgical interventions for IBD:
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...